Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Adverse Event
18%
Arm
18%
Bevacizumab
12%
Biopsy Technique
13%
Breast Cancer
58%
Carboplatin
18%
Carcinomatous Peritonitis
13%
Chemoradiotherapy
12%
Chemotherapy
71%
Childhood Cancer
41%
Cisplatin
16%
Colorectal Carcinoma
20%
Computer Assisted Tomography
13%
Cystectomy
14%
Disease
31%
Doxorubicin
12%
Drug Megadose
14%
Event Free Survival
22%
Fluorodeoxyglucose F 18
27%
Hazard Ratio
22%
High Dose Chemotherapy
13%
Hyperthermic Intraperitoneal Chemotherapy
18%
Kidney Tumour
57%
Lung Cancer
15%
Lymph Node
21%
Malignant Neoplasm
30%
Melanoma
20%
Metastatic Carcinoma
19%
Neoplasm
100%
Non Small Cell Lung Cancer
57%
Obstructive Sleep Apnea
20%
Overall Survival
56%
Pediatrics
27%
Pediatrics Patient
15%
Penis Carcinoma
14%
Polyethylene Terephthalate
24%
Positron Emission Tomography
32%
Positron Emission Tomography-Computed Tomography
12%
Preoperative Chemotherapy
18%
Prognostic Factor
17%
Progression Free Survival
12%
Radiation Therapy
49%
Randomized Controlled Trial
21%
Recurrent Disease
38%
Scintigraphy
12%
Squamous Cell Carcinoma
19%
Surgery
24%
Survival Rate
12%
Systemic Therapy
18%
Wilms' Tumor
91%
Keyphrases
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
17%
5-year Survival
19%
70-gene Signature
18%
Bevacizumab
21%
Breast Cancer
23%
Breast Cancer Patients
23%
Breast Cancer Risk
13%
Capecitabine
20%
Carboplatin
25%
Chemotherapy
48%
Cisplatin
19%
Colorectal Cancer
21%
Computed Tomography
15%
Confidence Interval
35%
Doxorubicin
14%
Dutch
31%
Erlotinib
14%
Event-free Survival
21%
Hazard Ratio
23%
Head-and-neck Cancer
17%
High Dose
13%
High Risk
19%
High-dose Chemotherapy
14%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
16%
Intermediate Risk
15%
International Society
16%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
16%
Metastatic Breast Cancer
15%
Neoadjuvant
15%
Netherlands
27%
Non-small Cell Lung Cancer (NSCLC)
36%
Obstructive Sleep Apnea-hypopnea Syndrome (OSAHS)
16%
Overall Survival
49%
Pediatric Oncology
30%
Penile Carcinoma
16%
Peritoneal Carcinomatosis
13%
Phase II Study
22%
Positron Emission Tomography
22%
Preoperative Chemotherapy
23%
Primary Tumor
15%
Progression-free Survival
16%
Prophylactic Cranial Irradiation
15%
Radiotherapy
38%
Randomized Phase III Trial
13%
Randomized Trial
22%
Renal Tumor
39%
Tumor
67%
Tumor Research
32%
Tumor Volume
14%
Wilms Tumor
76%
